mirtazapine and Acute Post-Traumatic Stress Disorder

mirtazapine has been researched along with Acute Post-Traumatic Stress Disorder in 21 studies

Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.

Research

Studies (21)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Structured Interview of Posttraumatic Stress Disorder (SIP)

Structured Interview of Posttraumatic Stress Disorder (SIP) is a 17-item clinician-administered scale for PTSD based on Diagnostic Statistical Manual-IV criteria. The SIP has excellent test-retest reliability (0.89; p=.00001), and internal consistency (Conbach α of 0.80). The SIP showed significant correlations with the DTS (r=0.67, p=.0001) and the Impact of Event Scale (r=0.49 p=.0001). Relative to the SCID diagnosis of PTSD, sensitivity, specificity, positive predictive value, negative predictive value, and efficiency values were 100% for all indices using a score of 20 on the SIP. Items are scored on a scale from 0-4 which are summed to yield a total score ranging from 0 to 68 (higher score means more symptomatic or worse outcome). A symptom is counted as positive if it is at least a 2 (moderate). (NCT00302107)
Timeframe: Primary outcome is measured at baseline and week 8 (primary endpoint) with primary outcome change scores calculated as week 8 minus baseline score.

Adverse Effects

as assessed by Side Effect Checklist (NCT01178671)
Timeframe: up to 24 weeks

Alternative Measure of PTSD Severity

as measured by the Short Posttraumatic Stress Disorder Rating Interview, which rates severity of PTSD from 0 (least severe) to 32 (most severe) (NCT01178671)
Timeframe: up to 24 weeks

Depression Severity

as measured by the 17-item Hamilton Rating Scale for Depression, which rates severity of depression on a scale from 0 (least depression) to 50 (greatest depression). (NCT01178671)
Timeframe: up to 24 weeks

PTSD Self-rated Severity

as measured by the PTSD Checklist which rates severity of PTSD from 17 (least severe) to 85 (most severe). (NCT01178671)
Timeframe: up to 24 weeks

PTSD Severity

PTSD severity will be measured by the Clinician-Administered Posttraumatic Stress Disorder Scale, from 0 (least severe) to 136 (most severe). (NCT01178671)
Timeframe: up to 24 weeks

Remission Status

Remitter as defined by Clinician Administered Posttraumatic Stress Disorders Scale total score <20 at endpoint (NCT01178671)
Timeframe: up to 24 weeks

Response Status

Responders defined by Clinician Administered Posttraumatic Stress Disorder Scale total score decreased by at least 30% compared with baseline and Clinical Global Impression improvement score of =1 or 2 at endpoint (NCT01178671)
Timeframe: up to 24 weeks

Sexual Functioning

as measured by Arizona Sexual Experiences Scale, which rates impairment in sexual functioning from 5 (least impaired) to 30 (most impaired). (NCT01178671)
Timeframe: up to 24 weeks

Sleep Quality

as measured by Pittsburgh Sleep Quality Index, which rates severity of impairment in sleep quality from 0 (least impaired) to 21 (most impaired). (NCT01178671)
Timeframe: up to 24 weeks

Time to Discontinuation of Study Treatment

(NCT01178671)
Timeframe: up to 24 weeks

Reviews

3 reviews available for mirtazapine and Acute Post-Traumatic Stress Disorder

Trials

7 trials available for mirtazapine and Acute Post-Traumatic Stress Disorder

Other Studies

11 other studies available for mirtazapine and Acute Post-Traumatic Stress Disorder